Exelixis Wins Appeal in Patent Case Against MSN Laboratories

MT newswire2026/08/31 19:25

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:25 PM EDT, 08/31/2026 (MT Newswires) -- Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories. The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot. Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added. Price: 54.35, Change: -0.10, Percent Change: -0.18

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41